Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Useful Bacteria Need Protection

04.07.2005


New forms of drugs for dysbacteriosis and other gastrointestinal disturbances are being developed by the Novosibirsk researchers with support of the International Science and Technology Center (ISTC).



A lot of Russians suffer from malfunction of gastrointestinal tract. The frequent reason for that is dysbacteriosis – disturbances of normal intestinal flora. To fight dysbacteriosis, physicians prescribe eubiotic drugs to patients, which contain bacteria necessary for digestion, for example, bifidumbacterin, lactobacterin, colibacterin, bificol, etc. The drugs are good, but upon intake they are destroyed in the stomach, due to that their efficiency reduces. To increase efficiency of eubiotics, they should be protected in some way.

This problem is being solved by the researchers of the State Research Center for Virology and Biotechnology “Vector” (“Vector-BiAlgam” close corporation (Koltsovo, Novosibirsk Region)) with support of the International Science and Technology Center (ISTC). Bacteria making part of the drugs need protection, and there are two main methods to defend them. The bacteria are either placed into a capsule – this is a capsulated form of drug, or they are placed on a special carrier - sorbent – this is an immobilized form.


The Novosibirsk researchers are developing and testing immobilized eubiotics. In this medication, cells of useful bacteria are placed on porous microcarrier SUMS-1 – aluminium oxide powder, the size of microparticles varying from 40 to 100 mkm, the surface of microparticles being covered by carbon (which is used in medicine as enterosorbent). Adsorption occurs on the carrier owing to both physical and chemical mechanisms. Proteins of the cellular wall of bacteria form chelates with the SUMS-1 surface, where magnesium serves as a complexing agent (chelation). In this case, active groups of bacteria’s proteins and lipoproteids turn out to be protected from the stomach’s aggressive acid medium. In the meantime, unprotected bifido- and lactobacteria lose more than 90 percent of their activity in the stomach, the immobilized ones go lossless through the stomach.

Chelates are known for their stability being dependent on the medium. As the stomach has acid medium, bacteria remains in it bound with sorbent. When the drug gets into lower parts of thin bowels, the chelate disintegrates due to increased. This is what is needed, because it is particularly in the thin bowels and than in the thick bowels that bifido- and lactobacteria get released from the carrier and start working. The released sorbent surface takes away toxins and metabolic products. SUMS-1 is a very efficient enterosorbent: it does not sorb small molecules - acids, carbohydrates, trace elements and it does not sorb large mass proteins either – transport proteins and enzymes. That is why the water-salt balance is not broken and bowel’ enzymatic activity does not decrease. Along with that, SUMS-1 actively binds proteins of medium mass, where toxins and products of uncomplete metabolism belong to. They are brought out of the organism together with the sorbent.

The Novosibirsk researchers have created complex eubiotic based on the SUMS-1sorbent, which includes consortium of several species of the most active cultures of bifido- and lactobacteria. These bacteria suppress reproduction of pathogenic, saprogenous and gas-producing microflora, they participate in peptic processes and synthesis of vitamins, in metabolism of trace elements and biologically active substances. On top of that, bifido- and lactobacteria act as immunostimulants.

New drugs underwent investigation at all levels. Testing them on laboratory animals, the researchers have made sure that they are non-toxic, do not cause side effects and at the same time destroy harmful intestinal flora and increase vital capacity of the organism. While clinical trials of the complex immobilized eubiotic are being prepared, the Novosibirsk State Medical Academy (based on the clinic) has already carried out clinical trials of its analogue called “Ecoflor”, which belongs to the category of bioactive nutritional supplements. 70 patients who were taking “Ecoflor” within two weeks have improved digestion and general habitus, and the gut organisms have become normal. The complex eubiotic production is still limited to pilot batches, and its analogue “Ecoflor” is already produced as a bioactive nutritional supplement.

And finally, it should be pointed out where new eubiotic drugs will be applied. They will be used not only for dysbacteriosis but also for toxin poisoning, enteric infection, pancreatitis, gastritis, ulcer and other chronic ailments, allergy, radiolesion and even tuberculosis and oncology treatment.

Sergey Komarov | alfa
Further information:
http://www.informnauka.ru

More articles from Life Sciences:

nachricht Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>